Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
CRISPR/Cas9 technology abolishes the BCR/ABL1 oncogene ef... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
CRISPR/Cas9 technology abolishes the BCR/ABL1 oncogene effect in chronic myeloid leukemia and restores normal hematopoiesis
0
Authors
Elena Vuelta
14 more
Elena Vuelta
•
José Ordóñez
12 more
•
Manuel Sánchez‐Martín
Published
September 4, 2020
Paper
Conversation
0
Reviews
0
Bounties
0
Loading PDF viewer…
Supporters
Support the authors with ResearchCoin
Tip RSC
Preprint Server
Topics
Biology
Cancer Oncology
Immunology
Hematology
Genetics
Show all topics
DOI
10.1101/2020.08.05.237610
License
CC-BY-NC-ND
Other Formats
PDF
Supporters
Support the authors with ResearchCoin
Tip RSC
Preprint Server
Topics
Biology
Cancer Oncology
Immunology
Hematology
Genetics
Show all topics
DOI
10.1101/2020.08.05.237610
License
CC-BY-NC-ND
Other Formats
PDF
